Modern combined lipid-lowering therapy can considerably increase life duration in patients with the rare genetic disease homozygous familial hypercholesterolemia.
May support longer survival with combined therapy in HoFH; leaves open optimal regimens in this rare disease.
Homozygous familial hypercholesterolemia is a rare genetic disease featuring extremely high of low-density lipoprotein blood level, cutaneous and tendon xanthomas and accelerated atherosclerosis with often manifestions in the first 2 decades of life, resulting to premature death due to atherosclerosis-related diseases. Modern combined lipid-lowering therapy is able to increase life duration considerably for these patients.
No takes yet. Share an insight, caveat, or question.
Zafiraki et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: